Hydroquinone, niacinamide and dark spots: questions about evidence

AAD distinguishes melasma from pigmentation following inflammation or injury, including acne, and from age or solar spots on sun-exposed areas. Some apparent age spots are other lesions, including skin cancer. Have a new, changing or uncertain spot assessed before trying to fade it; an article cannot establish its diagnosis.

Tell the clinician what you noticed and what you are uncertain about. A useful question is: “What makes this diagnosis fit, and is there anything else that needs to be ruled out?” That asks for an explanation of the assessment instead of asking the reader to identify a condition from a product description.

Likeness Dark Spot Cream lists hydroquinone 6%, kojic acid 6% and niacinamide (concentration unspecified).

Write the entire preparation beside any claim made for it. Is the evidence about this preparation, one ingredient on its own, or a different mixture? Ask that question before comparing percentages. Otherwise, a discussion can quietly move from a studied ingredient to a product that has not been evaluated in the same way.

Navarrete-Solís and colleagues’ 2011 full report studied 27 women with melasma. It used a randomized, double-blind split-face comparison for eight weeks, with sunscreen. The two sides belong to the same women; they are not 54 independent participants.

The paper contains impossible MASI confidence intervals and inconsistent phototype counts. Its statistics do not clearly explain paired or repeated-measure handling. There is no post-treatment recurrence assessment or explicit funding disclosure. We do not repair its numbers, chart MASI, infer independence, or turn nonsignificant differences into equivalence.

Both treated sides improved, but the trial did not establish equivalence. These limitations constrain interpretation; they do not prove that either ingredient has no benefit. The comparison cannot establish that combining them improves results or tolerability.

A transparent reading can preserve a study’s useful question while declining to repeat an unreliable number. Do not substitute a plausible value for a published error. An apparent typo may be easy to guess at, but a guess is not corrected source data. The original authors or a documented correction would need to resolve the discrepancy.

In a paired comparison, two observations are linked to one person. The important comparison must respect that link. Simply listing one group’s average beside another does not show how the within-person differences behaved. This is a general reason to ask about the analysis rather than treating two bars of similar height as proof of equal effects.

Also distinguish the question “Did something change?” from “Did one treatment outperform the other?” Both sides of a comparison can change while the evidence about their difference remains uncertain. Equivalence needs its own definition of an acceptably small difference and an analysis capable of assessing it. A nonsignificant result alone does not provide that definition.

FDA’s skin-product safety page, current May 11, 2026, says hydroquinone skin-lightening products are not approved for over-the-counter sale. Prescription access is different. FDA reports rash, facial swelling and potentially permanent discoloration called ochronosis; those reports do not estimate the risk of a particular prescription formula.

TRI-LUMA is a specific approved combination of hydroquinone 4%, tretinoin 0.05% and the corticosteroid fluocinolone acetonide 0.01%. Its indication is short-term treatment of moderate to severe facial melasma with sun avoidance and sunscreen. It is not a maintenance treatment; the label notes recurrence after discontinuation.

Its approval, results and directions do not transfer to Likeness.

FDA’s explanation of compounded medicines separates prescription access from FDA approval. An ingredient’s inclusion in an approved product does not approve every mixture containing it.

AAD includes light protection in pigment care: shade, protective clothing and broad-spectrum sunscreen of at least SPF 30; tinted products with iron oxide address visible light. It also notes that irritation can contribute to pigmentation and that melasma can recur. Discuss these issues with a clinician.

TRI-LUMA’s label includes irritation and pregnancy or nursing precautions. Ask how those topics apply to the exact preparation under consideration; this guide does not provide a personal course length, mixture or treatment schedule.

Agree on what would prompt another assessment and who should receive a question about an unexpected change. Ask how the clinician will distinguish the goal you started with from a new problem. A useful follow-up conversation needs a clear description of what changed, when you noticed it and what you were using, rather than a guessed explanation.

If your concern is fine lines, the tretinoin guide examines a different outcome. If it is the identity or route of a hormone cream, the estriol and estradiol guide addresses that question. These are separate reading paths, not a plan to combine treatments.

For this consultation, keep your questions in order: what is being assessed, what evidence is relevant and how the proposed decision will be reviewed. You can ask for the rationale even when you do not know the technical name of an ingredient. An explanation should connect the evidence to the recommendation without requiring you to fill in that connection yourself.